AI Unleashed: How GPT & Gemini Turned the Tables on Our 2025 Predictions, part I
By Jason Stoffer and Simran Suri
As early-stage consumer investors, we’re always dissecting trends and preferences — running surveys, crunching data and trying to see what’s next. We’ve always used AI tools like ChatGPT as handy research sidekicks — they’re great for quickly looking up stats, building tables and figures and going through large amounts of data. But, everything changed last week when our trusty AI tools cranked out more venture-scale ideas in five minutes than we’ve brainstormed in 5 weeks.
Here’s what happened: while fleshing out our 2025 Predictions for our research calendar, we ran the blog post through ChatGPT o1 and Gemini 2.0 using the following prompt:
We are Maveron, a venture capital firm focused on investments that can impact millions of lives. For each of the predictions below, can you please offer 5 ideas that have the potential to be huge venture-upside decacorns?
Within minutes, AI produced a treasure chest of ideas. We’d seen some coming, but others were so compelling and original that it felt like AI might actually be coming for our jobs in venture. We had originally planned to write a lengthy follow-up blog post to our 2025 Predictions post, sharing greater detail on business opportunities within each prediction our team is exploring this year. Instead, we’re sharing the raw results of our AI experiment — the ideas were too good to keep under wraps! We’ll be showing ChatGPT and Gemini’s business ideas, side-by-side across our key focus areas over the next 4 weeks, starting with Health.
If you’re a founder working on any of these ideas, please reach out! We’d love to learn more about your work (including how close these AI ideas are to your actual business).
Our Health focus began with a deep dive into the downstream impacts of GLP-1s, which included consumer surveys and primary research around preferences and willingness-to-pay for weight loss-friendly food, fitness classes and communities. While our initial POV in the space focused on deprescription from GLP-1s, our primary research has since pointed us in a few additional directions:
Food Regulation
While reducing processed food intake has proven health benefits, this isn’t entirely net-positive for consumers — the FDA is already investigating raw milk products for bird flu. It’s also not entirely net-positive for brands, who may have to adjust their supply chains and manufacturing operations.
Consumer Life Science
If DOGE pushes the FDA to allow the marketing and sale of drugs and devices after Phase 1 clinical trials, life sciences could become an investable consumer opportunity with the potential for venture-scale returns within a standard fund cycle.
Cravings x Convenience
Consumers are looking for the GLP-1 era’s 100-calorie snack pack, and F&B brands that can hit the intersection of cravings and convenience will thrive.
You can find our full 2025 Predictions post here.
